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Background: Single nucleotide polymorphism (SNP) 309 resulting in a T or G allele in the promoter of MDM2, the
negative regulator of p53, has been suggested to affect cancer predisposition and age of onset, primarily in
females. However, findings have been inconsistent in various cancers, and ethnicity appears to be a critical factor
influencing the effects of the SNP on cancer risk. An increasing trend has been observed in the prevalence of lung
cancers in non-smokers, especially females, though the underlying genetic basis is unclear.
Methods: We therefore examined the role of the SNPs in the p53 pathway (p53 codon 72 and MDM2 SNP309) on
lung cancer risk and prognosis of a life-time non-smoking female Chinese population, in a hospital-based case-
control study of 123 cases and 159 age-matched controls, by PCR analysis.
Results: Our findings reveal that the risk of lung cancer among individuals with the MDM2 SNP309 TT genotype
was 2.1 (95% CI 1.01-4.36) relative to the GG genotype, contrary to initial expectations that the GG genotype with
elevated MDM2 levels will increase cancer risk. Those who had this genotype in combination with the p53 Pro
allele had a risk of 2.5 (95% CI 1.2-5.0). There was however no effect of either polymorphism on age at diagnosis of
lung cancer or on overall survival.
Conclusions: The results thus demonstrate that the MDM2 SNP309 TT rather than the GG genotype is associated
with increased risk of lung cancer in this population, suggesting that other mechanisms independent of increased
MDM2 levels can influence cancer susceptibility.
Background
The TP53 tumour suppressor pathway plays a critical
role in cell cycle regulation and apoptosis in many can-
cers, including lung carcinomas [1], and variation in the
genes that regulate this pathway may exert an important
influence on tumour development, and hence, cancer
risk. Recent interest has focused on the murine double
minute-2 protein (MDM2), a nuclear phospoprotein that
inhibits p53 activity by promoting its degradation [2]. A
single nucleotide polymorphism (SNP309) in the MDM2
promoter has been found to influence transcription of
this gene via a greater affinity for the SP1 transcription
factor, and hence, individuals with the GG genotype have
higher MDM2 levels leading to attenuation of the p53
pathway [3,4]. This has been especially so in the case of
females, due to the involvement of the MDM2 SNP in
the estrogen receptor signaling pathway [3].
Several epidemiologic studies have evaluated this asso-
ciation with varying results. No overall association
between MDM2 SNP309 and lung cancer risk was
observed in recent studies in a European [5], North
American [6,7] and two Asian [8,9] populations. How-
ever, the GG genotype was observed to increase risk in
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panic Whites in the US [12]. In some cases, even though
there was no overall association noted with the MDM2
SNP309 and cancer susceptibility, substratification of
groups led to some association. For example, an
increased risk was correlated with the GG genotype only
in the adenocarcinomas, but not in the small cell, squa-
mous cell or non-small cell lung cancers (NSCLCs), or
when all lung cancer subtypes were grouped [9]. Other
studies pointed to an interaction with smoking status -
although no association was found between all lung can-
cers and the MDM2 SNP309, there was an elevated risk
of cancer susceptibility in smokers compared to non-
smokers in the same study [10]. Conversely, one study
found that the risk of lung cancer was higher among
individuals with the TT genotype - on stratification, this
association was restricted to males and to smokers [12].
A meta-analysis of seven studies concluded that the GG
genotype conferred a small but significant increased risk
(summary odds ratio [OR] 1.27; 95% confidence interval
[CI] 1.12-1.44) [13]. Because of the capacity of the poly-
morphism to enhance the inhibitory action of MDM2
on the p53 pathway, investigators have hypothesized
that the GG genotype would also negatively influence
prognosis in lung cancer. To date, two studies have
demonstrated that the GG genotype is associated with a
lower level of p53 expression [14] and with poorer sur-
vival [14,15].
A polymorphism at codon 72 of the p53 gene result-
ing in an arginine-to-proline (Arg/Pro respectively) sub-
stitution has also been shown to be varyingly associated
with cancer predisposition, possibly due to differences in
ethnicity and in background risk due to smoking
[16-18]. A meta-analysis of 13 epidemiologic studies
which examined this association reported that the sum-
mary odds ratio of lung cancer associated with the Pro/
Pro genotype was 1.18 (95% CI 0.99-1.41), and was 1.02
(95% CI 0.86-1.20) for Pro-carriers [19]. The Pro/Pro
genotype has also been associated with poorer prognosis
and less favorable clinical outcome in lung cancer
patients [14,20,21]. Moreover, significantly higher or a
lower prevalence of p53 gene mutations have been
noted in lung cancers among carriers of the Pro allele in
the Polish [22] or a Norwegian population [23], respec-
tively. These data highlight that ethnicity and other fac-
tors may have an impact on p53 functionality, with
respect to the SNP and mutational status.
The influence of gender and ethnic differences on
genetic determinants of lung cancer is increasingly
being recognized. Smoking accounts for the overwhelm-
ing majority of cases in Western populations and among
men, but lung cancer among non-smokers is now
known to be a distinct clinico-pathologic entity that is
as yet poorly understood [24,25]. We therefore sought
to examine if MDM2, through its role in the p53 path-
way, is associated with risk and prognosis of lung cancer
among Singapore Chinese women, a primarily non-
smoking population. In addition, as MDM2 SNP309 sta-
tus has been demonstrated to affect the overall age of
onset of various cancers, with differential effects in dif-




Participants were drawn from a hospital-based case-con-
trol study on lung cancer among Chinese women in Sin-
gapore [27]. Incident cases were primary lung cancers
diagnosed at any one of three major hospitals in the
country over the study period, and controls were patients
admitted to the same hospitals, frequency-matched by
age. Patients admitted for malignant or chronic respira-
tory conditions (chronic bronchitis, emphysema and
chronic asthma) were not eligible to participate as con-
trols. All participants provided written consent. Within
this study population, a consecutive sub-sample of parti-
cipants were asked, and consented to provide a blood
specimen for genetic analysis. Of these, 126 cases (95.2%
of which were pathologically confirmed) and 162 controls
were never smokers and form the basis for the current
report. The study was approved by the Ethics Committee
of the National Cancer Centre and the Institutional
Review Board of the National University of Singapore.
Demographic, smoking and other relevant information
was obtained by in-person interview with a trained
nurse. A lifetime non-smoker was defined by a negative
response to the question “Have you ever smoked a
cigarette or any other form of tobacco, at least once a
day for one year?”
Genomic DNA was prepared from peripheral blood
using the standard proteinase K-phenol-chloroform pro-
cedure and DNA was stored at -30°C till analysis.
Laboratory analysis
Genotyping was performed independently at the Depart-
ment of Community, Occupational and Family Medi-
cine, National University of Singapore, and at the
Laboratory of Molecular Carcinogenesis, National Can-
cer Centre. Genomic DNA from peripheral blood sam-
ples was used for PCR analysis of p53 using the
following primers: Forward: 5’-GAAGACCCAGGTCCA-
GATGA-3’ and Reverse: 5’-ACTGACCGTGCAAGTCA-
CAG-3’, this gave rise to a 216 bp product, followed by
BtgI digestion. The p53 P r oa l l e l eh a sau n i q u eBstUI
site that is absent in the Arg allele, resulting in bands of
different sizes as follow: 50 bp, 166 bp (Pro/Pro), 216 bp
(Arg/Arg) and 50 bp, 166 bp, 216 bp (Pro/Arg). Like-
wise, MDM2 promoter SNP309 was amplified as a 194 bp
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5’-CGGGAGTTCAGGGTAAAGG-3’ and Reverse: 5’-
TCGGAACGTGTCTGAACTTG-3’. Genotyping was then
performed by digestion using restriction enzyme MspAI.
T h eM D M 2p r o m o t e rS N P 3 0 9Ga l l e l eh a sau n i q u e
MspAI site that is absent in the T allele resulting in bands
of different sizes as follows: 49 bp, 145 bp (G/G), 194 bp
(T/T), 49 bp, 145 bp, 194 bp (G/T). MDM2 status
was also confirmed by sequencing reactions using the
following primers: Forward: 5’-CGGGAGTTCAGGG-
TAAAGGT-3’ and Reverse: 5’-AGCAAGTCGGTGCTTA
CCTG-3’, as described [26].
Statistical analysis
We used unconditional logistic regression to compute
adjusted odds ratios (ORs) and their corresponding 95%
confidence intervals (CIs) for the association between
lung cancer risk and MDM2 SNP309 and p53 codon 72
genotypes. ORs were adjusted for age (in years) and
birthplace. All participants were female, never smokers
and ethnic Chinese.
The Kruskal-Wallis test was carried out to evaluate
the differences in the age of onset of cancer among
patients with different genotypes, while Fisher’se x a c t
test was used to test the equivalence of distribution of
cancer stage among patients with different genotypes.
The Logrank test was performed to examine the differ-
ences between Kaplan-Meier-estimated overall survival
among patients with different genotypes. Analyses were
performed using STATA version 9.0 (Strata Corpora-
tion, College Station, TX USA) and SPSS for Windows
version 15.0 (SPSS Inc., Chicago, IL).
Results
Table 1 provides a description of relevant demographic
and other background characteristics of cases and con-
trols. They were similar in respect of age, years of edu-
cation, and cases were more likely to have been born
outside of Singapore than controls. They were also less
likely to consume fruit and vegetables, or to be exposed
to environmental tobacco smoke at home. Approxi-
mately three-quarters of the cases were
adenocarcinomas.
A total of 123 (97.6%) cases and 159 (98.1%) controls
were successfully genotyped for both polymorphisms.
Genotype frequencies were comparable with the
published literature and in keeping with the lower
prevalence of the T allele reported in Asian, relative to
Caucasian, populations [7,8,10-12]. The distribution of
genotype frequencies conformed to that expected
under the Hardy-Weinberg equilibrium for both
MDM2 SNP309 (p = 0.62) and TP53 codon 72
(p = 0.19).
MDM2 SNP309 TT genotype increases lung cancer risk
Risk of lung cancer was higher among individuals with
the MDM2 SNP309 TT genotype relative to the GG
genotype (OR 2.10, 95% CI 1.01-4.36) (Table 2). Hetero-
zygotes showed an intermediate risk (OR 1.42, 95% CI
0.80-2.52).
Analysis of the p53 codon 72 SNP revealed that the
presence of the p53 Pro allele was associated with a
small but non-significant increase in risk: odds ratios for
Arg/Pro and Pro/Pro genotypes were 1.21 (95% CI 0.67-
2.17) and 1.44 (95% CI 0.70-3.00), respectively (Table 2).
Table 1 Distribution of selected characteristics among cases and controls
1
Cases (n, %) Controls (n, %)
Age in years
2 (Mean ± S.D.) 62.0 ± 13.7 63.4 ± 12.3
Years of formal education (Mean ± S.D.) 3.5 ± 4.2 3.8 ± 4.8
Servings of fruit weekly (median, IQR) 3.9, 6.8 7.8, 10.1
Servings of vegetable weekly (median, IQR) 18.1, 16.0 20.6, 20.1
Birthplace
Singapore/Malaysia 82 (65.1) 130 (80.2)
China/other 44 (34.9) 32 (19.8)
Exposure to environmental tobacco smoke at home
Daily 46 (36.5) 72 (44.4)
Weekly < daily 16 (12.7) 15 (9.3)
Less than weekly 64 (50.8) 75 (46.3)
Histological subtype
Squamous/small cell carcinoma 14 (11.9)
Adenocarcinoma 85 (72.0)
Large cell undifferentiated/Not otherwise specified 19 (16.1)
1 All participants are Chinese women, cases and controls frequency-matched for age. A total of 126 cases and 162 controls were eligible, of which 123 and 159,
respectively, were successfully genotyped.
2 Refers to age at diagnosis (cases) and age at interview (controls)
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modified by p53 codon 72 status. The TT genotype con-
ferred an elevated risk (OR 2.42, 95% CI 1.16-5.03) only
among codon 72 Pro allele carriers (Table 2). However,
the interaction was not statistically significant (p = 0.06).
A similar magnitude of risk (OR 2.47, 95% CI 1.21-5.03)
(data not shown) was conferred by the TT, Arg/Pro,
Pro/Pro genotypes in combination, relative to the GG,
Arg/Arg genotypes.
Taken together, the data indicate that the TT geno-
type of MDM2 SNP309 is associated with increased
lung cancer risk.
p53 codon 72 polymorphism and MDM2 SNP309 status
does not influence the age of diagnosis of lung cancer
Kruskal-Wallis analysis indicated no association of the p53
codon 72 genotypes with age of onset in the study popula-
tion (p = 0.557); 50% of the population were diagnosed
between the ages of 60 and 63, regardless of the genotypes
(Figure 1A), and the median age of onset for the Arg/Arg,
Arg/Pro and Pro/Pro groups were found to be 64.5, 60.0
and 63.0, respectively. Similar analysis of the effect of the
various MDM2 SNP309 genotypes also revealed no asso-
ciation between them and the age of onset of lung cancer
(p = 0.338) (Figure 1B). The median age of onset for the
T/T, T/G and G/G groups were found to be 59.0, 65.0 and
63.5, respectively (Figure 1B). Combined analysis of the
effects of both p53 and MDM2 alleles also did not reveal
any significant differences in the age of onset of the disease
(p = 0.718)(data not shown).
Table 2 Risk of lung cancer in relation to MDM2 SNP309 and p53 codon 72 polymorphisms
Genotype Cases (n = 123) Controls (n = 159) Age- and birthplace-
adjusted
1odds ratio (95% CI)
No. (%) No. (%)
MDM2 SNP309
GG 29 (23.6) 51 (32.1) 1.00
TG 65 (52.8) 83 (52.2) 1.42 (0.80-2.52)
TT 29 (23.6) 25 (15.7) 2.10 (1.01-4.36)
P53 codon 72
Arg/Arg 28 (22.8) 42 (26.1) 1.00
Arg/Pro 69 (56.1) 88 (54.7) 1.21 (0.67-2.17)
Pro/Pro 26 (21.1) 31 (19.3) 1.44 (0.70-3.00)
Combined genotype
2
P53 codon 72 MDM2 SNP309
Arg/Arg GG/TG 24 (85.7%) 32 (76.2%) 1.00
TT 4 (14.3%) 10 (23.8%) 0.58 (0.15-2.22)
ArgPro/ProPro GG/TG 69 (73.4%) 102 (87.2%) 1.00
TT 25 (26.6%) 15 (12.8%) 2.42 (1.16-5.03)
1 Adjusted for age in years and birthplace (China-born, Singapore/Malaysia-born). All individuals were lifetime non-smoker Chinese women.
2 P (interaction) = 0.06
Figure 1 MDM2 SNP309 and p53 codon 72 polymorphism do
not affect onset-age of lung cancer in female non-smoker
patients. A-B. The cumulative incidence of cancer cases in the
population was plotted as a function of age of onset of lung
cancer, comparing the various p53 codon 72 (A) and MDM2 SNP309
(B) genotypes. No significant differences were noted with respective
to both the different p53 and MDM2 genotypes. n = 21 for Arg/Arg,
n = 16 for Pro/Pro and n = 47 for Arg/Pro and n = 22 for T/T, n =
19 for G/G and n = 54 for G/T.
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polymorphism and MDM2 SNP309 SNP
97 patients with survival data available were included in
the survival analysis. The median follow-up time was
10.1 months. Analysis of overall survival revealed no sta-
tistically significant differences with respect to the var-
ious p53 genotypes (p = 0.263) (Figure 2A). The median
survival for patients with Arg/Arg, Arg/Pro and Pro/Pro
p53 genotypes were 5.47 (CI 95% 3.17-10.23), 10.87 (CI
95% 7.53-18.70) and 8.93 (CI 95% 4.33-11.63) months,
respectively (Figure 2A). Similarly, no significant differ-
ences were observed with respect to the various MDM2
genotypes and overall survival (p = 0.267) (Figure 2B),
and the median survivals for the various MDM2
SNP309 alleles were 11.17 (CI 95% 3.60-33.80) (T/T),
10.10 (CI 95% 5.47-11.90) (T/G) and 9.57 (CI 95% 5.17-
18.70) (G/G) months (Figure 2B).
Combined analysis of the effects of both p53 and
MDM2 polymorphisms on overall survival also did not
reveal any significant differences among the nine differ-
ent genotypes (p = 0.367) (data not shown).
Discussion
In summary, we show here that the MDM2 SNP309 TT
genotype is associated with a higher risk of lung cancer
among never smoking women in the Chinese popula-
tion. The presence of the p53 codon 72 Pro allele did
not lead to a statistically significant interaction or mate-
rially affect the magnitude of this risk. Neither of the
MDM2 nor p53 polymorphisms evaluated showed any
impact on survival or age of onset of lung cancer in this
population.
Our study population is unique in consisting solely of
non-smoking women, who could potentially be informa-
tive with regard to risk factors that operate indepen-
dently of tobacco smoking. The finding that the MDM2
TT genotype increases risk was unexpected, since as
described earlier, many studies that have reported asso-
ciations have found increased risk with the GG genotype
that are consistent with the impact of this genotype on
MDM2 RNA and protein levels, and hence, on inhibi-
tion of p53 [3]. To our knowledge, only one study has
examined the combined effect of MDM2 and p53 poly-
morphisms and lung cancer, and this was also con-
ducted in a Chinese population [10]. The results showed
a multiplicative effect, with a 4.5-fold higher risk in
those with the GG, Pro/Pro genotypes relative to TT,
Arg/Arg. However, our findings suggesting that TT gen-
otype can be a susceptibility factor are not entirely sur-
prising, given the recent observations. Recent work
using large numbers of breast cancer samples in the
Chinese female population also revealed that the TT
genotype predisposes to accelerated onset of cancers
[26], and that the GG genotype reduced risk of leukemia
[28]. Moreover, one other study has noted association of
increased lung cancer risk with the TT genotype in the
Chinese population [12], supporting our data. Thus, it is
possible that the association of the G or the T alleles
with increased cancer risk or onset age may be influ-
enced by ethnicity and by environmental factors unique
to that particular population. More in depth larger scale
studies are now required to further extend these
findings.
How does the TT genotype lead to increased cancer
risk is at present not well understood, but there is evi-
dence to suggest that the role of MDM2 in tumorigen-
esis may vary in a gender-specific manner, and between
smokers and never smokers. Thus, it is not inconceiva-
ble that the mechanisms by which MDM2 modulates
lung cancer risk can differ between populations. The
role of hormones in carcinogenesis is rapidly emerging
as a complex, but important pathway. Estrogen signal-
ing, in particular the estrogen receptor (ER), is known
Figure 2 Polymorphic status of p53 codon 72 or MDM2
SNP309 does not affect overall survival of female non-smoker
lung cancer patients. A-B. Kaplan-Meier overall survival curves for
all patients with different p53 (A) or MDM2 (B) genotypes. No
significant differences were noted with respective to the different
MDM2 or p53 genotypes alone or in combination. n = 21 for Arg/
Arg, n = 16 for Pro/Pro and n = 47 for Arg/Pro and n = 22 for T/T,
n = 19 for G/G and n = 54 for G/T.
Chua et al. BMC Cancer 2010, 10:88
http://www.biomedcentral.com/1471-2407/10/88
Page 5 of 7to play a direct role in MDM2 transcription, regulating
its expression [29]. The G allele of SNP309 increases
the affinity of the MDM2 promoter for Sp1, a co-tran-
scriptional activator for the estrogen receptor, and was
associated with increased MDM2 expression. Consis-
tently, Bond et. al. showed that the effect of the MDM2
polymorphism (GG) was gender-specific and enhanced
in women with active estrogen signaling pathways [30].
Therefore, one would envisage that the TT genotype is
associated with reduced MDM2 levels. However, MDM2
has also been shown to negatively regulate ER expres-
sion [31]. Thus, it is possible that reduced MDM2 levels
expected in TT individuals could lead to elevated ER
expression, and hence may elevate cancer risk - a
hypothesis that requires further investigation. Given that
estrogen receptors are expressed in lung tumours, parti-
cularly adenocarcinomas, and these cells are responsive
to estrogen [32,33], it is possible that hormonal path-
ways provide an alternative mechanism by which
MDM2 influences lung cancer risk in this population.
Alternatively, other MDM2-dependent pathways could
be modified in the TT subjects, leading to cancer sus-
ceptibility. In this respect, no studies have evaluated if
specific signaling pathways are associated with the
MDM2 SNPs. Given the emergence of an association of
the TT genotype with cancer susceptibility in various
studies, such analyses would provide further mechanistic
insights.
Conclusions
In conclusion, our findings suggest that the MDM2
SNP309 TT genotype is a risk factor for lung cancer in
never-smoker Chinese females. The difference between
our results and others highlights the possibility that
MDM2 may operate via unique mechanisms among
non-smoking Asian women.
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